Minireviews
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2023; 11(12): 2657-2669
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2657
Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
Federica Crispino, Andrea Michielan, Mauro Grova, Chiara Tieppo, Marta Mazza, Teresa Marzia Rogger, Franco Armelao
Federica Crispino, Andrea Michielan, Chiara Tieppo, Marta Mazza, Teresa Marzia Rogger, Franco Armelao, Azienda Provinciale per i Servizi Sanitari, Gastroenterology and Digestive Endoscopy Unit, Santa Chiara Hospital, Trento 38122, Italy
Mauro Grova, Inflammatory Bowel Disease Unit, Department of Medicine, Azienda Ospedaliera Ospedali Riuniti, Villa Sofia-Cervello, Palermo 90146, Italy
Author contributions: Crispino F, Michielan A designed the study; Grova M, Tieppo C, Mazza M, Rogger TM, Armelao F analysed and interpreted data; Crispino F, Grova M, Michielan A drafted the manuscript; Tieppo C, Mazza M, Rogger TM study supervision; Armelao F critically revised the manuscript for important intellectual content; Crispino F, Grova M, Armelao F, Tieppo C, Mazza M, Rogger TM, Michielan A approved the manuscript.
Conflict-of-interest statement: Dr. Michielan has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Andrea Michielan, MD, Doctor, Azienda Provinciale per i Sevizi Sanitari, Gastroenterology and Digestive Endoscopy Unit, Santa Chiara Hospital, Largo Medaglie d’oro 9, Trento 38122, Italy. andrea.michielan@apss.tn.it
Received: January 20, 2023
Peer-review started: January 20, 2023
First decision: February 22, 2023
Revised: March 10, 2023
Accepted: March 29, 2023
Article in press: March 29, 2023
Published online: April 26, 2023
Core Tip

Core Tip: Clinicians are still uncertain about whether and when to consider stopping conventional therapies in inflammatory bowel disease (IBD) for fear of disease relapse. Our review aims to shed light on the optimal discontinuation strategies for biologics and the small molecule tofacitinib in IBD.